Skip to content
Font Size

FDA Urges Safe Use of Certain Inhaled Asthma Medicines

The Food and Drug Administration (FDA) has issued recommendations on how inhaled medications called Long-Acting Beta-Agonists (LABAs) should be used to treat asthma.

On Feb. 18, 2010, the agency said

Recommended Related to FDA Center

FDA Unveils New Cigarette Health Warnings

Consumers are getting a glimpse of warnings images that will be alternating on all cigarette packages and advertisements within 15 months—an effort by health officials to discourage smoking by bringing Americans face to face with tobacco-related disease. The Food and Drug Administration unveiled the nine, color images—including some of  bodies ravaged by disease—at a news conference. The images, which are paired with text health warnings, are required under the 2009 Family Smoking Prevention and...

Read the FDA Unveils New Cigarette Health Warnings article > >

  • LABAs should never be used alone in the treatment of asthma in children or adults
  • when LABAs are needed, they be used for the shortest time possible to achieve asthma control. They are then to be discontinued, if possible, to limit the long-term use

FDA's actions are based on agency analyses of studies showing an increased risk of severe worsening of asthma symptoms, leading to hospitalization in pediatric and adult patients—as well as death in some patients—using the treatment for asthma.

LABAs are available as single ingredient products, or in combination with a corticosteroid medication. (The reason that some LABAs are offered as single-ingredient products is that not all asthma controller medicines are able to be made into a combination product.)

The drugs affected by FDA's announcement include

  • the single-ingredient products Serevent (generic name: salmeterol) and Foradil (formoterol)
  • the combination medications Advair (salmeterol and fluticasone) and Symbicort (formoterol and budesonide)

How LABAs Work

LABAs help people with asthma or a lung condition called chronic obstructive pulmonary disease (COPD) breathe easier. They are also used for exercise-induced bronchospasm, which is asthma that is triggered by vigorous physical activity.

Taken through the mouth using an inhaler or a nebulizer, LABAs relax the muscles of the airways to allow more air to flow into and out of the lungs. Their effects last for at least 12 hours.

FDA's recommendations only apply to the use of LABAs in the treatment of asthma.

“Although these medicines play an important role in helping some patients control asthma symptoms, our review of the available clinical trials determined that their use should be limited, whenever possible, due to an increased risk of serious asthma exacerbations and death,” says Badrul Chowdhury, M.D., director of FDA's Division of Pulmonary and Allergy Products.

“The risks of hospitalization and poor outcomes are of particular concern for children," says Dianne Murphy, director of FDA’s Office of Pediatric Therapeutics. "Parents need to know that their child should not be on a LABA alone.”

Additional Advice

In addition to following the recommendations issued on Feb. 18, FDA advises patients to

  • know that LABAs do not relieve sudden-onset asthma symptoms. Patients should always have a rescue inhaler, such as an albuterol inhaler, to treat sudden-onset asthma symptoms
  • know that, if they need a LABA plus an asthma controller medication that is not available as a combination product, they should work with their health care professionals to ensure that each individual medication is taken correctly
  • read the Medication Guide included in each LABA
  • talk with their health care professionals to learn the warning signs of worsening asthma, and to discuss any questions they have about the use of LABAs

Other FDA Actions